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Inhibitors of glycogen breakdown regulate glucose homeostasis by limiting glucose production in diabetes. Here we demonstrate that
restrained glycogen breakdown also inhibits cancer cell proliferation and induces apoptosis through limiting glucose oxidation, as well
as nucleic acid and de novo fatty acid synthesis. Increasing doses (50–100mM) of the glycogen phosphorylase inhibitor CP-320626
inhibited [1,2-
13C2]glucose stable isotope substrate re-distribution among glycolysis, pentose and de novo fatty acid synthesis in MIA
pancreatic adenocarcinoma cells. Limited oxidative pentose-phosphate synthesis, glucose contribution to acetyl CoA and de novo
fatty acid synthesis closely correlated with decreased cell proliferation. The stable isotope-based dynamic metabolic profile of MIA
cells indicated a significant dose-dependent decrease in macromolecule synthesis, which was detected at lower drug doses and
before the appearance of apoptosis markers. Normal fibroblasts (CRL-1501) did not show morphological or metabolic signs of
apoptosis likely due to their slow rate of growth and metabolic activity. This indicates that limiting carbon re-cycling and rapid
substrate mobilisation from glycogen may be an effective and selective target site for new drug development in rapidly dividing cancer
cells. In conclusion, pancreatic cancer cell growth arrest and death are closely associated with a characteristic decrease in glycogen
breakdown and glucose carbon re-distribution towards RNA/DNA and fatty acids during CP-320626 treatment.
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Tumour cell proliferation involves special metabolic adaptation to
increased macromolecule synthesis, primarily increased synthesis
of RNA, DNA and fatty acids, which triggers an increased need for
glucose to be shunted into ribose-phosphate and acetyl-CoA
precursor synthesis pathways. Entering frequently the ‘S’ phase of
a tumour cell’s life cycle requires the rapid breakdown of the
intracellular glucose store glycogen, which is regulated by the brain
(foetal) type glycogen phosphorylase (GP) enzyme complex
(Shimada et al, 1999). Therefore, limiting glycogen breakdown is
a strong signal for tumour cells of inadequate substrate glucose
availability, which decelerates cycle progression and likely induces
apoptosis. Numerous GP inhibitors (GPIs) have been synthesised
targeting various substrate or cofactor binding sites, such as the
AMP stimulatory, purine nucleoside and indole-binding sites
(Hoover et al, 1998; Treadway et al, 2001). Inhibitors of the
complex that bind to cyclin-dependent kinases (CDKs), such as
flavopiridol, decelerate glycogen breakdown and are currently
being evaluated in clinical trials for the treatment of gastro-
intestinal cancers (Kelland, 2000). 5-Chloro-1H-indole-2-car-
boxylic acid (1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-
oxoethyl) amide, CP-320626, was identified as a potent inhibitor
of human liver glycogen phosphorylase-b (GP-b) with properties
of selective and specific allosteric binding to the enzyme complex
in close proximity to the AMP allosteric regulator and catalytic
sites (Oikonomakos et al, 2000). The compound exerts its
inhibitory effects by stabilising the less active T state of the GP
complex, providing both a highly specific recognition site and
clearly delineated mechanism of action that are of significant
benefit in the search for improved GP inhibitors. CP-320626 bears
more selective and effective binding properties than those of
flavopiridol compounds, and the efficacy of its antiproliferative
action and mechanisms involved in limiting human cancer growth
are yet to be reported. In particular, whether and how inhibiting
the GP complex with CP-320626 effectively limits substrate
utilisation for macromolecule synthesis within the highly activated
glucose metabolic network of tumour cells is of great interest.
In this paper, we report significant changes in glucose carbon re-
distribution among major metabolic pathways for macromolecule
synthesis in pancreatic adenocarcinoma cells treated with CP-
320626, using the [1,2-
13C2]glucose stable isotope-based dynamic
metabolic profiling (SIDMAP) approach to track and quantify such
changes using previously established methods (Boros et al, 2003;
Green, 2003). The observed metabolic changes are correlated with
the induction and appearance of cell cycle arrest and apoptosis-
related molecular markers. Our data reveal that the metabolic
profile characteristic of limited synthesis from glucose of
nucleotide macromolecule precursors and fatty acids precedes
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sthe appearance of cell cycle arrest and apoptosis-related molecular
markers following inhibition of GP by CP-320626. These results
provide new information about the pathways and mechanisms
through which inhibition of glycogen breakdown results in
insufficient macromolecule synthesis to support proliferation,
consistent with the metabolic hypothesis of cell growth regulation
and apoptosis formation in pancreatic cancer (Boros et al,
2002a,b).
MATERIALS AND METHODS
The tracer for this metabolic profiling study, stable isotope
[1,2-
13C2]-D-glucose, was purchased with 499% purity and 99%
isotope enrichment for each position from Cambridge Isotope
Laboratories, Inc. (Andover, MA, USA). CP-320626 was kindly
provided by Pfizer Inc. (Groton, Connecticut) for the study.
Cells and cell culture
Human pancreatic ductal adenocarcinoma MIA PaCa-2 cells
(American Type Culture Collection (ATCC) CRL1420) and control
CRL-1501 human fibroblasts were purchased from ATCC. MIA
PaCa-2 cells have an average doubling time of 40h in DMEM with
10% foetal bovine serum and 2.5% horse serum (Gibco/BRL,
Gaitersburg, MD, USA) in the presence of antibiotics. The cells
were incubated at 371C, 5% CO2 and 95% humidity, and passed by
using trypsin 0.25% (Gibco/BRL) no more than 10 times after
receipt from the ATCC and prior to use in this study. MIA cells
have previously been used in both in vitro and in vivo experiments
and responded to treatments with pentose cycle inhibitors and
glycolysis enzyme inhibitors with characteristic metabolic profile
changes showing restricted macromolecule synthesis, which
correlated with decreased proliferation with great specificity
(Boros et al, 1997). CRL-1501 human immortalised fibroblasts
were used in this study to compare normal and tumour cell
sensitivities to GP inhibitor treatment in an escalating regime of
drug treatment from 25 to 100mM CP-320626.
Confluent cultures (75%) of MIA or CRL-1501 cells were
incubated in [1,2-
13C2]-D-glucose-containing media (100mgdl
 1
total concentration¼5m M; 50% isotope enrichment – that is, half
unlabelled glucose, half labelled with the stable isotope
13C tracer).
Cells were plated at a density of 10
6 per T75 culture flask and CP-
320626 added in a concentration range of 25–100mM, dissolved in
10% DMSO – 90% culture media. Control cultures were treated
with vehicle only. The doses of CP-320626 for the present study
were selected based on in vitro experiments demonstrating that
this drug effectively controls GP activity in the presence or absence
of glucose in human cells in the 10–100mM dose range (Andersen
and Westergaard, 2002). In separate experiments, MIA cells were
treated with graded doses of 2-deoxy-D-glucose (2-DOG) to
compare the efficacy of the antiproliferative effects of CP-320626
to the antiproliferative effects of 2-DOG, an established glycolysis
inhibitory substrate. Glucose and lactate levels in the medium were
measured using a Cobas Mira chemistry analyzer (Roche
Diagnostics, Pleasanton, CA, USA).
RNA ribose stable isotope studies
RNA ribose was isolated by acid hydrolysis of cellular RNA after
Trizol purification of cell extracts. Total RNA amounts were
assessed by spectrophotometric determination, in triplicate
cultures. Ribose was derivatised to its aldonitrile acetate form
using hydroxylamine in pyridine with acetic anhydride (Supelco,
Bellefonte, PA, USA) before mass spectral analyses. We monitored
the ion cluster around m/z 256 (carbons 1–5 of ribose; chemical
ionisation (CI)) and m/z 217 (carbons 3–5 of ribose) and m/z 242
(carbons 1–4 of ribose; electron impact ionisation (EI)) to
determine molar enrichment and the positional distribution of
13C in ribose. By convention, the base mass of
12C-compounds
(with their derivatisation agents) is given as m0, as measured by
mass spectrometry as described elsewhere (Boros et al, 2002a,b).
Ribose molecules labelled with a single
13C atom on the first
carbon position (m1) recovered from RNA were used to gauge the
ribose fraction produced by direct oxidation of glucose through
the G6PD pathway. Ribose molecules labelled with
13C on the first
two carbon positions (m2) were used to measure the fraction
produced by transketolase. Doubly labelled ribose molecules (m2
and m4) on the fourth and fifth carbon positions were used to
measure the molar fraction produced by triose phosphate
isomerase and transketolase.
Lactate
Lactate from the cell culture media (0.2ml) was extracted by
ethylene chloride after acidification with HCl. Lactate was
derivatised to its propylamine-heptafluorobutyrate ester form
and the m/z 328 (carbons 1–3 of lactate; CI) was monitored for
the detection of m1 (recycled lactate through the PC) and m2
(lactate produced by the Embden–Meyerhof–Parnas pathway) for
the estimation of pentose cycle activity (Lee et al, 1998a). In this
study, we recorded the m1/m2 ratios in lactate produced and
released by MIA pancreatic adenocarcinoma cells in order to
determine pentose cycle activity vs anaerobic glycolysis in
response to CP-320626 treatment.
Glutamate
Glutamate label distribution from glucose is suitable for determin-
ing glucose oxidation vs anabolic glucose use within the TCA cycle,
also known as anaplerotic flux. Tissue culture medium was first
treated with 6% perchloric acid and the supernatant was passed
through a 3cm
3 Dowex-50 (Hþ) column. Amino acids were eluted
with 15ml 2 N ammonium hydroxide. To further separate
glutamate from glutamine, the amino-acid mixture was passed
through a 3cm
3 Dowex-1 (acetate) column, and then collected with
15ml 0.5 N acetic acid. The glutamate fraction from the culture
medium was converted to its trifluoroacetyl butyl ester (TAB).
Under EI conditions, ionisation of TAB-glutamate produces two
fragments, m/z 198 and 152, corresponding to C2–C5 and C2–C4
of glutamate (Lee et al, 1996). Glutamate labelled on the 4–5
carbon positions indicates pyruvate dehydrogenase activity, while
glutamate labelled on the 2–3 carbon positions indicates pyruvate
carboxylase activity for the entry of glucose carbons to the TCA
cycle. TCA cycle anabolic glucose utilisation is calculated based on
the m1/m2 ratios of glutamate (Leimer et al, 1977).
Fatty acids
Palmitate, stearate, cholesterol and oleate were extracted after
saponification of cell pellets in 30% KOH and 100% ethanol using
petroleum ether. Fatty acids were converted to their methylated
derivative using 0.5 N methanolic-HCl. Palmitate, stearate and
oleate were monitored at m/z 270, 298 and 264, respectively, with
the enrichment of
13C-labelled acetyl units, which reflect synthesis,
elongation and desaturation of the new lipid fraction as
determined by mass isotopomer distribution analysis (MIDA) of
different isotopomers (Lee et al, 1995, 1998b).
Gas chromatography/mass spectrometry (GC/MS)
Mass spectral data were obtained on the HP5973 mass-selective
detector connected to an HP6890 gas chromatograph. The settings
were as follows: GC inlet 2501C, transfer line 2801C, MS source
2301C, MS Quad 1501C. An HP-5 capillary column (30m length,
250mm diameter, 0.25mm film thickness) was used for glucose,
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sribose and lactate analyses. As transketolase has the highest
metabolic control coefficient in the nonoxidative branch of the
pentose cycle (Sabate et al, 1995; Comin-Anduix et al, 2001), we
use the term transketolase throughout the paper. It should be
noted, though, that transketolase and transaldolase, besides other
enzymes, are all participants in nonoxidative pentose cycle
metabolism in human cells.
In vitro cell proliferation assay
The in vitro testing was accomplished by seeding MIA PaCa-2 cells
into 96 well (Falcon 3072, Franklin Lakes, NJ, USA) flat bottom
proliferation plates (5000cellswell
 1). On the second day, the
culture media were replaced by 2% FBS-DMEM (minimum growth
media). Three full plates were assigned either to 50 or 100mM CP-
320626 treatment regimens as follows: cells in the first column
(eight wells) on each plate were used as controls without treatment,
and the second through 12th columns were treated with the
compounds under testing. One extra plate without treatment was
used to characterise the natural growth patterns of MIA cells on
the 96-well plates during the study period, and it was used to
correct for differences occurring due to culturing conditions other
than experimental interventions. Promega (Madison, WI) MTS in
vitro cell viability/proliferation assay was performed to investigate
cell density and cell viability in response to increasing concentra-
tions of CP-320626. Treatments were discontinued 24h prior to the
proliferation assay by replacing the culture media with 50ml
minimum growth DMEM. The assay was performed by adding
50ml of tetrazolium dye solution to 50ml of cell culture media for
4h. Then the stop solution was added (de-ionised sterile water,
100ml) and the formazan product of the tetrazolium salt was
measured by a spectrophotometer at 490nm.
TUNEL apoptosis assay
The terminal deoxynucleotidyl transferase (TdT)-biotinylated 16-
deoxy-UTP nick end labelling (TUNEL) apoptosis assay allows the
recognition of apoptotic nuclei in cell preparations fixed on slides
by Fragment End Labelling (FragEL) of DNA. MIA cells were fixed
at 5 10
6cellsml
 1 density in 1% paraformaldehyde in PBS, at pH
7.4 for 10min at room temperature. In all, 100ml of the cell
suspension from the trypsinised culture was dried on a silanised
microscope slide, and then quenched in 3.0% hydrogen peroxide
in PBS for 5min at room temperature. Samples were rinsed twice
with PBS for 5min each in a Coplin jar before treatment with
working strength TdT enzyme, as described in the ApopTag In Situ
Apoptosis Detection protocol and Kit (Intergen Co., Purchase, NY,
USA).
Data analysis and statistical methods
Each experiment was carried out using triplicate cell cultures for
each condition within each experiment and experiments were
repeated once. Mass spectroscopic analyses were carried out by
three independent automatic injections of 1ml samples by the
automatic sampler, and accepted only if the standard sample
deviation was less than 1% of the normalised peak intensity.
Statistical analysis was performed using the Student’s t-test for
unpaired samples. Two-tailed significance at the 99% confidence
interval (m72.58s), Po0.01, indicated significant differences in
glucose carbon metabolism in control and CP-320626-treated MIA
cells, as shown below.
RESULTS
The stable isotope-based dynamic metabolic profiling (SIDMAP)
approach has been successful in determining pentose cycle
activity, glycolysis, the contribution of the two branches of the
pentose cycle to nucleic acid synthesis, de novo fatty acid synthesis
and acetyl-CoA glucose enrichment in HepG2 liver and MIA
pancreatic adenocarcinoma cells, as described previously (Boros
et al, 1997, 2002ab). The MIA cell line showed a close correlation
between limited cell proliferation and decreased [1,2-
13C2]glucose
substrate flow towards RNA/DNA and fatty acid synthesis in
negative and positive control drug testing metabolic profiling
studies (Boren et al, 2001). Using the same approach for the
present study, we incubated human pancreatic MIA adenocarci-
noma cells with [1,2-
13C2]glucose in the presence or absence of CP-
320626 in order to determine
13C-label distribution in RNA ribose,
lactate and glutamate, and to determine the contribution of glucose
carbons to de novo nucleic and fatty acid synthesis, glycolysis and
TCA cycle anaplerotic flux. Based on the number of
13C-labelled
carbons present in the extracted small molecular weight inter-
mediary metabolites, the ratio of metabolite synthesis via each
pathway was determined.
The optical cell count of MIA pancreatic adenocarcinoma
cultures using a haemocytometer before and after 72h of dose-
escalating CP-320626 treatment indicated a dose-dependent
inhibition of cell growth in MIA cultures (Figure 1A). CP-320626
completely inhibited cell proliferation as compared to the starting
cell number at the beginning of the in vitro cell proliferation study;
however, it was not clear to us whether this dose-dependent
inhibition of cell growth was attributable to limited cell prolifera-
tion or to increased cell death. Evaluation of the cultures using a
phase-contrast microscope revealed only a few floating (separated
or dead) cells, which points to limited cell growth due to cell cycle
arrest. The TUNEL assay indicated a dose-dependent appreciable
increase in apoptosis induction in MIA cell cultures after treatment
with either 50 or 100mM CP-320626. The frequency of apoptotic
cells increased from 4 to 28%, respectively (Figure 1B). CRL-1501
human fibroblasts failed to exhibit growth retardation or apoptosis
in proliferation and TUNEL assays using 25, 50, 75 or 100mM CP-
320626 (Figure 1C and D).
Optical densitometry (OD) of the cultures also indicated a dose-
dependent rapid decrease in cell proliferation as revealed by the
MTS assay (Figure 2). CP-320626 and 2-DOG-treated cultures
showed similar growth characteristics with significant inhibition of
cell proliferation. The glucose metabolite 2-DOG swiftly causes
cycle arrest and apoptosis in tumour cells due to a characteristic
decrease in glycolysis and pentose cycle substrate flow (Aft et al,
2002); however, CP-320626 was more effective in inhibiting
proliferation and oxidative metabolism, as indicated by the sharp
decrease of MTS staining of treated MIA cultures with GP inhibitor
drug.
Cell number-adjusted glucose consumption and lactate release
indicated no significant changes in cellular glucose consumption
or lactate release into the culture media after 25 or 50mM CP-
320626 treatment, signifying that MIA cells responding to this GP
inhibitor drug well maintain both glucose uptake and viability. The
average glucose consumption was 16ng24h
 110
 6 MIA cells and
the average lactate production was 11nM24h
 110
 6 cells, with no
significant change after treatment with CP-320626.
However, we observed discernible significant changes in
intracellular glucose carbon re-distribution among major glu-
cose-utilising macromolecule synthesis pathways in response to
CP-320626 treatment. Figure 3 reveals the [1,2-
13C2]glucose stable
isotope–based dynamic metabolic profile (SIDMAP) of MIA cells.
The SIDMAP panel indicates that 25 and 50mM CP-320626
treatment decreases CO2 release from glucose significantly
(Figure 3; panel A), and that there is a dose-dependent 7.8 and
49.6% decrease in direct glucose oxidation in the pentose cycle via
G6PDH and its recycling into lactate through transketolase and
transaldolase (Figure 3; panel B). It is also revealed from the
SIDMAP that there is a 33% decrease in nucleic acid (RNA)
13C
enrichment (Figure 3; panel C) and a 94.4% decrease in TCA cycle
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sglucose anaplerosis after 50mM CP-320626 treatment (Figure 3;
panel D). The continued metabolic profile is also consistent with
an 8.7 and 56.2% decrease in acetyl-CoA glucose
13C enrichment,
and a 26.6 and 88.4% decrease in de novo fatty acid palmitate
synthesis from glucose after 25 and 50mM CP-320626 treatment,
respectively (Figure 4). On the other hand, CRL-1501 cells
exhibited no
13C tracer accumulation into palmitate, stearate or
oleate, indicating the lack of de novo fatty acid synthesis from
glucose and less dependence on rapid glycogen turnover for
survival and growth.
The metabolic profile and apoptosis formation in control human
CRL-1501 fibroblast cell line cultures were not affected by GP
inhibitor treatment at doses identical to that of MIA cell cultures.
Apoptosis formation was observed but remained between 1 and
5% in all control and CP-320626-treated CRL-1501 cultures
(Figure 1; panels C and D).
DISCUSSION
Glycogen phosphorylation is the first step in glycogenolysis, which
releases glucose from glycogen as glucose-1-phosphate (G-1-P).
Other than its contribution to maintaining blood glucose home-
ostasis, little is known of G-1-P’s role in cell proliferation. Since G-
1-P is part of the hexose phosphate moieties, it is an immediate
precursor for many downstream reactions within the glucose
metabolic network. These include glycolysis, pentose synthesis,
energy generation and fatty acid synthesis. Our experimental data
prove that, even though glycogen is not the direct precursor of
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Figure 2 Optical density (OD) of MIA cultures after 72h dose-
escalating CP-320626 treatment in the MTS cell proliferation/survival assay.
This test indicates significantly fewer MIA cells with deprived oxidative
metabolism after increasing doses of CP-320626 treatment. This experi-
ment was performed in comparison with 2-deoxy-D-glucose, which is a
well-known growth-inhibitory substrate through cell cycle arrest and
apoptosis (n¼8; mean7s.d.; *Po0.05, **Po0.01).
Figure 1 (A) Cell count before and after 72h dose-escalating CP-
320626 treatment of MIA pancreatic adenocarcinoma cells in culture. Cell
numbers before the study and 72h later in response to 50mM CP-320626
treatment are not statistically different from the starting cell number.
Control cells were grown for 72h with vehicle only. (B) TUNEL assay
indicates 4% apoptotic MIA cells formation in 50mM CP-320626-treated
cultures, which increases about seven-fold, to 28%, after 100mM CP-
320626 treatment. (C) Cell count before and after 72h dose-escalating
CP-320626 treatment of CRL-1501 human fibroblasts. (D) TUNEL assay
indicates only 1–5% apoptotic CRL-1501 cell formation in 50mM CP-
320626-treated cultures. (n¼6; meanþs.d.; *Po0.05, **Po0.01).
Glycogen phosphorylase and tumour proliferation
W-NP Lee et al
2097
British Journal of Cancer (2004) 91(12), 2094–2100 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
spentose production, it indirectly affects pentose synthesis and fatty
acid synthesis rates in addition to affecting other distal metabolic
reactions. The impact of GP inhibition on these distal metabolic
reactions is significant and extensive. We observed significant
reversions in the extent of glucose utilisation for ribose and fatty
acid synthesis even at the lowest doses of CP-320626 well before
significant increase in cell cycle arrest or apoptosis induction
occurred.
When the GP inhibitor CP-320626 hinders glucose metabolic
pathways, MIA cells experience restricted ability to proliferate in
culture although they maintain metabolic activities as indicated by
13C tracer accumulation into all studied metabolites. They continue
consuming glucose and producing lactate after both 25 and 50mM
treatments with CP-320626. These changes are consistent with
continued cell viability, but lack of proliferation that is expressive
of cell cycle arrest. However, further increase (doubling) in drug
concentration induces a seven-fold enhancement of apoptosis.
Tumour cells heavily rely on all available extra- and intracellular
glucose sources for the rapid synthesis of nucleotides, amino acids
and fatty acids, which is demonstrated by the depleted glycogen
pool of transformed cells (Hughes, 1976; Karnik et al, 1981; Bismut
et al, 1995). It is evident from the metabolic profile reported here
that the ability of MIA cells to progress in the cell cycle is severely
impeded by limited glycogen breakdown in the presence of CP-
320626 and that the cell cycle arrest readily progresses into
apoptosis with higher doses of the drug. As the chemical structure
and binding characteristics of CP-320626 are several-fold more
effective and are more specific to the GP enzyme protein than
those of flavopiridol (Hoover et al, 1998), it is evident that the
antiproliferative action of CP-320626 is mediated through direct
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Figure 4 Continued SIDMAP reflecting decreased fatty acid synthesis in
MIA cells after treatment with increasing doses of the glycogen
phosphorylase inhibitor CP-320626. In control cultures, about 18% of
acetyl units and about 52% of intracellular palmitate arise from glucose,
expressed as per cent (%) of the total. CP-320626 treatment decreased
both acetyl unit synthesis and de novo fatty acid palmitate synthesis from
glucose in a dose-dependent fashion (n¼6; meanþs.d.; *Po0.05,
**Po0.01).
Figure 3 SIDMAP of MIA cells after treatment with increasing doses of
the glycogen phosphorylase inhibitor CP-320626 indicates severe changes
in intracellular glucose carbon distribution. Carbon dioxide release from
glucose is decreased, as demonstrated by a fall in
13C/
12C ratios in panel A;
the decrease in pentose cycle direct glucose oxidation and recycling into
lactate is shown in panel B as per cent (%) of glycolysis; the decrease in
nucleic acid (RNA) ribose
13C molar enrichment is shown in panel C as
13C
P
mn, and the severe decrease in TCA cycle anabolic glucose use
(anaplerosis) is shown in panel D as per cent (%) of glucose oxidation
within the cycle (n¼6; meanþs.d.; *Po0.05, **Po0.01).
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smetabolic substrate flow changes and not through the interruption
of the cyclin-dependent kinase pathway (Kelland, 2000). It has
been documented that GP A and B activities are increased in the
muscle of diabetic pancreatic cancer patients (Liu et al, 2000).
Therefore, therapies of pancreatic cancer using specific GP
inhibitors may improve host glucose status and insulin sensitivity
via improving skeletal muscle glycogen synthesis and glycogen
storage, while inhibiting tumour cell proliferation and glucose
cycling through glycogen.
Metabolic profile changes reported herein are followed by the
appearance of molecular markers for apoptosis, pointing to the
fact that if tumour cells experience interruption of the altered
metabolic network that turns glycogen rapidly into nucleic acid
ribose and fatty acids, that interruption will impose a blockage on
cell cycle progression. The reported significant alterations in
substrate re-distribution and macromolecule synthesis indicate
that regulators of key metabolic processes of substrate utilisation
play important roles in the induction of apoptosis in MIA
pancreatic adenocarcinoma cells. It is likely that this scenario
exists in all rapidly dividing human malignant cells.
It is evident that SIDMAP studies combined with molecular
techniques are remarkably valuable tools in revealing metabolic
mechanisms that result in cell cycle arrest and apoptosis. Human
tumour cells readily become wholesale re-distributors of glucose
and they primarily utilise this substrate for macromolecule
synthesis. The malignant phenotype’s inherent biochemical
mandate to effectively compete for and preferentially obtain all
glucose available to it makes glucose tracers optimal tools for
SIDMAP studies, as shown consistently herein. Such studies
provide a precise elucidation of key molecular mechanisms
responsible for cell cycle events and apoptosis, thereby suggesting
which specific metabolic enzyme inhibitors are likely to have
significant potential as antiproliferative agents. The metabolic
changes in CP-320626-treated MIA cells are consistent with
decreased synthesis of key precursor intermediates participating
in macromolecule synthesis, DNA/RNA formation and membrane
assembly (Figure 5). The prominent decrease observed in the
contribution of glucose to nucleic acid ribose synthesis indicates
that glycogen and its rapid breakdown into glucose are required
for promoting tumour cell proliferation. In turn, the lack of
adequate glycogen breakdown and glucose cycling ensures that
apoptosis will ensue. This observation may identify several new
enzymatic target sites in the apoptotic pathway of mammalian
cells, which is regulated primarily through a metabolic balance
between glycolysis, the pentose cycle and glycogen synthesis/
breakdown. The fact that apoptosis formation remained less than
5% in all control and CP-320626-treated CRL-1501 human
fibroblast cultures indicates that a significant diversity exists
between transformed and nontransformed cells in their sensitivity
to inhibiting rapid glycogen breakdown as a substrate for the
synthesis of cell proliferation-related macromolecules, primarily
RNA and fatty acids. For example, CRL-1501 human fibroblasts do
not utilise glucose carbons for de novo fatty acid synthesis in the
presence of more than 2% foetal bovine serum in the culture
medium. This metabolic diversity by the differential use of glucose
in CRL-1501 fibroblasts and MIA cells is important to understand
tumour cells’ sensitivity to GP inhibitor treatment.
These findings suggest that defective ribose and fatty acid
synthesis are the likely causes of cell cycle arrest and apoptosis in
cultured MIA pancreatic adenocarcinoma cells in response to GP
inhibitor treatment, and provide a strong rationale for the use of a
GP inhibitor as an adjunct for the treatment of human cancer in
clinical trials. Finally, the observation that inhibition of glycogen
phosphorylation induces cell cycle arrest and apoptosis strongly
supports the metabolic hypothesis that the regulation of cell
growth and cell death in human cancers occurs through the
substrate level regulation of macromolecule synthesis, which
determines cell cycle progression and apoptosis formation.
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Figure 5 Metabolic profile changes associated with glycogen phosphorylase inhibitor treatment in MIA pancreatic adenocarcinoma cells. MIA cells in the
absence of CP-320626 utilise glucose as the major substrate for de novo nucleic acid and fatty acid synthesis as shown to the left (A). CP-3206262 limits
glycogen breakdown as indicated on the panel to the right (B). As a result, tumour cells become less capable of synthesising nucleic acid ribose and fatty
acids, which significantly limits their cycle progression and growth. One interesting feature of this metabolic profile is that it appears at lower concentrations
of CP-320626 and precedes apoptosis formation. (G6P: glucose -6-P; G1P: glucose-1-P; F6P: fructose-6-P; GAP: glyceraldehyde-3-P; PYR: pyruvate;
OAA: oxaloacetate).
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